These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 1844820)

  • 1. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
    Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ
    Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.
    Saxena R; Shaw GL; Relling MV; Frame JN; Moir DT; Evans WE; Caporaso N; Weiffenbach B
    Hum Mol Genet; 1994 Jun; 3(6):923-6. PubMed ID: 7951238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.
    Marez D; Legrand M; Sabbagh N; Lo-Guidice JM; Boone P; Broly F
    Hum Genet; 1996 May; 97(5):668-70. PubMed ID: 8655150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism.
    Douglas AM; Atchison BA; Somogyi AA; Drummer OH
    Pharmacogenetics; 1994 Jun; 4(3):154-8. PubMed ID: 7920695
    [No Abstract]   [Full Text] [Related]  

  • 5. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.
    Evert B; Griese EU; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 1994 Oct; 350(4):434-9. PubMed ID: 7845481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374.
    Crespi CL; Steimel DT; Penman BW; Korzekwa KR; Fernandez-Salguero P; Buters JT; Gelboin HV; Gonzalez FJ; Idle JR; Daly AK
    Pharmacogenetics; 1995 Aug; 5(4):234-43. PubMed ID: 8528270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F; Meyer UA
    Pharmacogenetics; 1993 Jun; 3(3):123-30. PubMed ID: 8101460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
    J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
    Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
    Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
    Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
    Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.
    Yokota H; Tamura S; Furuya H; Kimura S; Watanabe M; Kanazawa I; Kondo I; Gonzalez FJ
    Pharmacogenetics; 1993 Oct; 3(5):256-63. PubMed ID: 8287064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
    Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
    Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
    Gaedigk A; Blum M; Gaedigk R; Eichelbaum M; Meyer UA
    Am J Hum Genet; 1991 May; 48(5):943-50. PubMed ID: 1673290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells.
    Evert B; Eichelbaum M; Haubruck H; Zanger UM
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Mar; 355(3):309-18. PubMed ID: 9089660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
    Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
    Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel CYP2D6 allele associated with poor metabolism of sparteine in a Japanese population.
    Kondo I; Yonaha M; Okano K; Gonzalez FJ; Kanazawa I
    Pharmacogenetics; 1991 Dec; 1(3):161-4. PubMed ID: 1688247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.